NEW YORK (GenomeWeb News) – Vermillion today said that it has inked an equity investment deal with certain investors to purchase up to $31.5 million of the firm's stock.

The Austin, Texas-based molecular diagnostics firm said that Oracle Investment Management, Jack Schuler, Matthew Strobeck, and other investors have agreed to make an initial investment in the company by purchasing 8 million shares of Vermillion common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.